
Danaher (DHR) Stock Forecast & Price Target
Danaher (DHR) Analyst Ratings
Bulls say
Danaher has demonstrated strong performance with performance obligations increasing to $4.9 billion in 2Q25, indicating solid demand and a healthy backlog from prior quarters. The company’s Life Sciences segment is projected to achieve a growth ramp of approximately 4.5% in 4Q25, supported by favorable comparisons in Genomics, robust performance in China, and strategic new product launches. Furthermore, the stability in book-to-bill ratios at around 1.0x highlights balance in order intake versus fulfillment, contributing to a positive outlook for Danaher's operational momentum.
Bears say
Danaher's outlook appears negative, as the percentage of obligations expected to be recognized as revenue within the next 12 months has decreased from 48% to 46%, indicating a potential slowdown in revenue recognition. Additionally, the company faces several risks that could further impede growth, including geopolitical disruptions, foreign exchange fluctuations, and the possibility that high-growth end-markets, particularly in China, do not recover as anticipated. Furthermore, revenue guidance for the Biotechnology and Life Sciences sector came in slightly below expectations, contributing to concerns regarding overall financial performance.
This aggregate rating is based on analysts' research of Danaher and is not a guaranteed prediction by Public.com or investment advice.
Danaher (DHR) Analyst Forecast & Price Prediction
Start investing in Danaher (DHR)
Order type
Buy in
Order amount
Est. shares
0 shares